Berizzi Alice E, Gentry Patrick R, Rueda Patricia, Den Hoedt Sandra, Sexton Patrick M, Langmead Christopher J, Christopoulos Arthur
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Mol Pharmacol. 2016 Oct;90(4):427-36. doi: 10.1124/mol.116.104182. Epub 2016 Jul 26.
Recently, the first subtype-selective allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been described, but their molecular mechanisms of action remain unknown. Using radioligand-binding and functional assays of inositol phosphate (IP) accumulation and Ca(2+) mobilization in a recombinant cell line stably expressing the human M5 mAChR, we investigated the effects of the positive allosteric modulator (PAM), ML380, and negative allosteric modulator, ML375. In functional assays, ML380 caused robust enhancements in the potency of the full agonists, acetylcholine (ACh), carbachol, and oxotremorine-M, while significantly increasing the maximal response to the partial agonist, pilocarpine. ML380 also demonstrated direct allosteric agonist activity. In contrast, ML375 displayed negative cooperativity with each of the agonists in a manner that varied with the pathway investigated and progressively reduced the maximal pilocarpine response. Radioligand-binding affinity cooperativity estimates were consistent with values derived from functional assays in some instances but not others, suggesting additional allosteric effects on orthosteric ligand efficacy. For ML375 this was confirmed in IP assays performed after reduction of receptor reserve by the alkylating agent, phenoxybenzamine, as it reduced the maximal ACh response. In contrast, ML380 enhanced only ACh potency after receptor alkylation, with no effect on maximal response, consistent with studies of the M1 mAChR with the prototypical PAM, BQZ12. Interaction studies between ML380 and ML375 also indicated that they most likely used an overlapping allosteric site. Our findings indicate that novel small-molecule modulators of the M5 mAChR display mixed mechanisms of action compared with previously characterized modulators of other mAChRs.
最近,已报道了M5毒蕈碱型乙酰胆碱受体(mAChR)的首批亚型选择性变构调节剂,但其作用的分子机制仍不清楚。我们使用放射性配体结合以及在稳定表达人M5 mAChR的重组细胞系中进行的肌醇磷酸(IP)积累和Ca(2+)动员的功能测定,研究了正变构调节剂(PAM)ML380和负变构调节剂ML375的作用效果。在功能测定中,ML380使完全激动剂乙酰胆碱(ACh)、卡巴胆碱和氧化震颤素-M的效力显著增强,同时显著增加了对部分激动剂毛果芸香碱的最大反应。ML380还表现出直接的变构激动剂活性。相比之下,ML375与每种激动剂表现出负协同性,其方式随所研究的途径而变化,并逐渐降低毛果芸香碱的最大反应。放射性配体结合亲和力协同性估计在某些情况下与功能测定得出的值一致,但在其他情况下不一致,这表明对正构配体效力存在额外的变构效应。对于ML375,在用烷基化剂苯氧苄胺降低受体储备后进行的IP测定中证实了这一点,因为它降低了最大ACh反应。相比之下,ML380在受体烷基化后仅增强了ACh效力,对最大反应没有影响,这与用原型PAM BQZ12对M1 mAChR的研究一致。ML380和ML375之间的相互作用研究还表明,它们很可能使用重叠的变构位点。我们的研究结果表明,与先前表征的其他mAChR调节剂相比,新型M5 mAChR小分子调节剂表现出混合的作用机制。